These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 21438346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
    Koskela-Niska V, Pukkala E, Lyytinen H, Ylikorkala O, Dyba T.
    Int J Cancer; 2013 Oct 01; 133(7):1680-8. PubMed ID: 23526244
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Riskt.duennebier@dkfz-heidelberg.de.
    Breast Cancer Res Treat; 2010 Apr 01; 120(3):727-36. PubMed ID: 19672706
    [Abstract] [Full Text] [Related]

  • 10. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
    Biglia N, Maffei S, Lello S, Nappi RE.
    Gynecol Endocrinol; 2010 Nov 01; 26(11):804-14. PubMed ID: 20586550
    [Abstract] [Full Text] [Related]

  • 11. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.
    Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI.
    Int J Cancer; 2010 Jan 15; 126(2):483-9. PubMed ID: 19588504
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
    Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A.
    Climacteric; 2005 Dec 15; 8(4):342-51. PubMed ID: 16390769
    [Abstract] [Full Text] [Related]

  • 15. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
    Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA.
    J Clin Oncol; 2003 Dec 01; 21(23):4314-21. PubMed ID: 14645420
    [Abstract] [Full Text] [Related]

  • 16. Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma.
    Koskela-Niska V, Pukkala E, Lyytinen H, Ylikorkala O, Dyba T.
    Int J Cancer; 2015 Oct 15; 137(8):1947-52. PubMed ID: 25846583
    [Abstract] [Full Text] [Related]

  • 17. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):595-602. PubMed ID: 15840882
    [Abstract] [Full Text] [Related]

  • 18. [Hormone replacement therapy in postmenopausal women and breast cancer risk: impact of estrogens deprivation and timing hypothesis].
    Brettes JP, Mathelin C.
    Gynecol Obstet Fertil; 2007 Nov 20; 35(11):1092-4. PubMed ID: 17996474
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.